Last reviewed · How we verify
NCT06730607: MYOCARDITIS-VT
Image-Based Prediction of Ventricular Tachycardias in Post-Myocarditis Patients: an International Multicenter Case-control Study
trial in Myocarditis in 150 participants. Currently enrolling.
30 December 2026
Quick facts
| Lead sponsor | Centro Medico Teknon |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 2 December 2024 |
| Primary completion | 30 December 2026 |
| Estimated completion | 30 December 2026 |
| Sites | 3 locations across Italy, Spain |
Conditions studied
- Myocarditis — all drugs for Myocarditis →
- Ventricular Arrhythmia — all drugs for Ventricular Arrhythmia →
Sponsor
Centro Medico Teknon — full company profile →
Who can join
18 and older, any sex, with Myocarditis or Ventricular Arrhythmia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Ventricular arrhythmias (VAs) are frequently associated with structural heart diseases (SHD) such as myocardial infarction, myocarditis, and non-ischemic cardiomyopathies. Myocardial fibrotic tissue plays a central role in the genesis and the maintenance of re-entrant VAs associated with post-myocarditis sequelae and late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) has proven to be a useful tool for the non-invasive characterization of the scarred tissue and the underlying arrhythmogenic substrate. Moreover, a post-processing imaging platform named ADAS 3D LV (ADAS3D Medical SL, Barcelona, Spain) allows to analyze the CMR-derived data and to characterize the scar architecture, differentiating between dense (scar core zone) and more diffuse (border zone \[BZ\]) fibrosis, and identifying the BZ channels (BZCs) that are strands of healthy myocardial tissue within zones of unexcitable tissue and connect areas of normal myocardium. It was described that BZCs could serve as slow-conducting reentrant pathways and are critical to entail VA in ischemic and non-ischemic heart disease. However, the pathophysiological role and the correlation between scar architecture and VAs in post-myocarditis patients is yet to be defined. To date, the standard-of-care evaluation for primary prevention implantable cardioverter-defibrillator (ICD) therapy is LVEF-based, leading to the fact that the contemporary rate of appropriated therapies is very low. Moreover, events may also occur in patients with normal to moderately depressed LVEF, which is particularly relevant, as it constitutes the most prevalent population of patients exposed to an increased risk of VAs. Multiple studies reported that LGE at CMR is a strong and specific predictor of VT occurrence and sudden death in post-myocarditis patients. There were reported cases in which even after the normalization of LVEF, the extension of LGE, the scar architecture, and the presence of BZCs at cMR analysis are determinants of the arrhythmic risk in post-myocarditis patients. The Investigators sought to evaluate the usefulness of CMR-derived scar architecture analysis to predict the occurrence of VT events in an international, multicenter, case-control study on unselected post-myocarditis patients without previous arrhythmia evidence. Aim of the study is also to assess the net reclassification improvement (NRI) for the indication of primary prevention ICD implantation using CMR data and post-processing data as compared to LVEF-based indication
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06730607
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myocarditis
Currently open trials in the same condition.
- NCT06889662 — GEAM Study Aims At Assessing the Role of Genetic Testing in Patients with Arrhythmic Myocarditis. · recruiting
- NCT06566209 — FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis · recruiting
- NCT07086144 — Efficacy of a Myocardial Panel in the Management and Treatment of Pediatric Myocarditis · NA · recruiting
- NCT06158698 — CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine · Phase 3 · recruiting
- NCT06010199 — Risk Stratification Value of Biomarkers in Patients With Myocarditis · recruiting
Other Centro Medico Teknon trials
Trials by the same sponsor.
- NCT07159685 — Sex-Based Differences of LA: Impact on AF Ablation. · not yet recruiting
- NCT07112716 — SVC-isolation in Redo-AF Ablation With Isolated PV · NA · not yet recruiting
- NCT07402798 — Anesthetic Safety of High-Frequency, Very-Low Tidal Volume Ventilation With Controlled Peak Pressure During Atrial Fibri · completed
- NCT07330791 — Right Phrenic Nerve Localization on CT for Ablation · completed
- NCT06730464 — Image-Based Prediction of Ventricular Tachycardia Events in Non-ischemic Cardiomyopathy · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06730607 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centro Medico Teknon
- Last refreshed: 12 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06730607.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing